SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company’s website. RedTail is C ...

Core Insights - Calidi Biotherapeutics is set to present data on its innovative use of BiTEs in solid tumors through its RedTail platform at the AACR Immuno-Oncology conference from February 18-21, 2026 [1] Company Overview - Calidi Biotherapeutics is a biotechnology company focused on developing targeted genetic medicines, utilizing its proprietary RedTail platform for systemic delivery to metastatic sites [5] - The RedTail platform employs an engineered enveloped oncolytic virus designed to evade immune clearance, allowing effective delivery of genetic medicines to tumor sites [5] Product Development - The lead candidate from the RedTail platform, CLD-401, is engineered to express high levels of IL-15 superagonist, which activates T-cells within the tumor microenvironment [2][3] - CLD-401 is currently in IND-enabling studies and targets non-small cell lung cancer, head and neck cancer, and other tumor types with significant unmet medical needs [6] - The company plans to submit an Investigational New Drug (IND) application for CLD-401 by the end of 2026 [4] Technological Advancements - The RedTail platform has shown the ability to remodel the tumor microenvironment and induce T-cell activation, which is crucial for overcoming the limitations of BiTEs in solid tumors [3] - The platform allows for the simultaneous expression of multiple tumor-localized payloads, enhancing the potential for effective treatment [3] Strategic Initiatives - Calidi is actively pursuing strategic partnerships to accelerate the clinical development of its RedTail platform and broaden its impact in the biotechnology sector [4]